WHC is still in active development. Read this to understand our approach.
depiction of MLQRZXNZHAOCHQ-UHFFFAOYSA-N.svg
isomerdesign

3-Methylfentanyl

Check on isomerdesign

pubchem

Mefentanyl

Check on pubchem

drugmap

3-Methylfentanyl

Check on drugmap

wiki

3-Methylfentanyl

Check on wiki

Data

InChI: InChI=1S/C23H30N2O/c1-3-23(26)25(21-12-8-5-9-13-21)22-15-17-24(18-19(22)2)16-14-20-10-6-4-7-11-20/h4-13,19,22H,3,14-18H2,1-2H3

Synonyms: DTXSID30962228, R-26800,R-26800,Propanamide, N-(3-methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-, Propanamide, N-(3-methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-, HSDB 8379,CHEBI:61092,cis-3-Methylfentanyl,DEA No. 9813,UNII-QVU94XE61A, 3-MF,N-(3-Methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide,(RS)-N-(3-Methyl-1-phenethyl-4-piperidyl)-N-phenyl-propanamide, C23H30N2O, 3-methyl-fentanyl, N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide,Epitope ID:153511, 3-METHYLFENTANYL, AC1Q5I8R,F 7209,DB01571, DEA No. 9813,3-MF (trans), AC1L1WAM,3-Methylfentanyl,N-[3-Methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide-trans,QVU94XE61A, MLQRZXNZHAOCHQ-UHFFFAOYSA-N, 42045-86-3,3-METHYLFENTANYL, Epitope ID:153511, SCHEMBL2337401,N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide, CTK1D6517,3-Methylfentanil, 3-Methylfentanil,3-Methylfentanyl trans, F 7209, DB01571,Mefentanyl,Q2030844,Mefentanyl (trans),Discontinued see: M205505, N-(3-Methyl-1-(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide,CHEMBL4748291,SCHEMBL2337401,42045-86-3,N-(3-methyl-1-phenethyl-4-piperidyl)-N-phenylpropanamide,HSDB 8379,N-(3-Methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide,3-MF, N-(3-Methyl-1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide, CHEBI:61092, LS-119344

Estimated data

Solubility: -4.158 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 96.5% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.